论文部分内容阅读
目的 研究原位逆转录多聚酶链反应技术（Ｉｎ Ｓｉｔｕ－ＲＴ ＰＣＲ）在检测慢性粒细胞白血病（ＣＭＬ）ｂｃｒ／ａｂｌ融合基因中的应用价值及其意义。方法：用 Ｉｎ Ｓｉｔｕ－ＲＴ ＰＣＲ方法测定 ＣＭＬ病人ｂｃｒ／ａｂｌ融合基因表达量。结果：在不破坏细胞完整性条件下细胞系Ｋ５６２和ＣＭＬ病人检测到ｂｃｒ／ａｂｌＲＮＡ的扩增产物，表现为细胞浆内出现蓝紫色颗粒，计算这种阳性细胞的百分率来相对定量地检测ＣＭＬ病人ｂｃｒ／ａｂｌ ｍＲＮＡ的表达水平，这种检测技术的敏感性达１０－４水平以上。结论：Ｉｎ Ｓｉｔｕ－ＲＴ ＰＣＲ可以相对定量地检测ＣＭＬ病人ｂｃｒ／ａｂｌ ｍＲＮＡ的表达，直观地评价α－干扰素（α－ＩＦＮ）、骨髓移植（ＢＭＴ）等治疗ＣＭＬ的疗效，本检测方法敏感性高，又可用做微小残留病（ＭＲＤ）的检测。
Objective To investigate the value and significance of in situ reverse transcription polymerase chain reaction (In Situ-RT PCR) in detection of bcr/abl fusion gene in chronic myelogenous leukemia (CML). Methods: The expression of bcr/abl fusion gene in CML patients was measured by In Situ-RT PCR. RESULTS: Bcr/ablRNA amplification products were detected in patients with K562 and CML cell lines without destroying cell integrity. Blue-violet particles appeared in the cytoplasm. The percentage of positive cells was calculated to quantitatively detect CML patients. The expression level of bcr/abl mRNA, the sensitivity of this detection technique is more than 10-4 level. Conclusion: In Situ-RT PCR can quantitatively detect the expression of bcr/abl mRNA in CML patients, and intuitively evaluate the efficacy of α-IFN and bone marrow transplantation (BMT) in the treatment of CML. High, it can also be used for detection of minimal residual disease (MRD).